(Reuters) -U.S. drugmaker Pfizer (NYSE:) stated on Wednesday it's withdrawing its sickle cell illness remedy Oxbryta from all markets the place it's authorised, citing dangers of a painful complication and...
By Ludwig Burger (Reuters) - Sanofi (NASDAQ:)'s most superior a number of sclerosis (MS) drug candidate has missed the principle aim of two late-stage trials to deal with relapsing types...
